Who Owns AstraZeneca?
AstraZeneca is owned by AstraZeneca PLC, a public pharmaceutical company listed on the London Stock Exchange and Nasdaq under ticker AZN and headquartered in Cambridge, England. Formed in 1999 by the merger of Sweden's Astra AB and Britain's Zeneca Group, the brand covers medicines including Tagrisso and Farxiga and generated $58.7 billion in fiscal 2025 revenue, making it a top-ten global pharmaceutical company.
Parent Company
Founded
1999
Status
Publicly Traded
Headquarters
Who Owns AstraZeneca?
- Parent Company: AstraZeneca PLC
- Ownership Type: Wholly owned
- Company Type: Publicly Traded
- Stock Ticker: London Stock Exchange (also Nasdaq): AZN
| Brand | Parent Company | Ownership Type |
|---|---|---|
| AstraZeneca | AstraZeneca PLC | Wholly owned |
Where to Buy
Disclosure: We may earn commission from purchases
AstraZeneca on AmazonAdvertisement
History of AstraZeneca
- Founded: 1999
- Founders: Astra AB, Zeneca Group
The 1999 merger combined Astra's respiratory and gastrointestinal strength with Zeneca's oncology and cardiovascular portfolio. Early products included Losec, Seroquel, and Zoladex, with Crestor, Symbicort, and Nexium driving the 2000s.
The 2007 MedImmune acquisition established biologics, and Soriot's 2012 appointment refocused the company on pipeline investment. The 2010s delivered Tagrisso, Imfinzi, Lynparza, and Farxiga as multi-billion-dollar franchises, while the 2014 Bristol-Myers Squibb diabetes alliance buyout consolidated ownership of Onglyza and dapagliflozin.
The 2021 Alexion acquisition for $39 billion added the rare disease segment, and the 2020 Oxford-AstraZeneca COVID-19 vaccine brought global visibility before being withdrawn in 2024. Fiscal 2025 delivered $58.74 billion in revenue with 16 blockbuster medicines and 16 positive Phase III readouts.
Advertisement
About AstraZeneca PLC
Is AstraZeneca a British or Swedish company?
AstraZeneca is a British-Swedish company. It was formed in 1999 by merging Sweden's Astra AB with the UK's Zeneca Group. Legally it is a UK public limited company headquartered in Cambridge, England, though it retains major operations in Sweden.
Is AstraZeneca publicly traded?
Yes. AstraZeneca PLC trades primarily on the London Stock Exchange under ticker AZN, where it is one of the largest FTSE 100 companies, and it maintains a secondary listing on Nasdaq under the same ticker.
When was AstraZeneca founded?
AstraZeneca was formed in 1999 through the Astra-Zeneca merger. Its roots extend to 1913, when Astra was founded in Sweden, and to Zeneca's 1993 spin-off from Imperial Chemical Industries.
Who leads AstraZeneca?
Pascal Soriot has been chief executive officer since 2012. He is credited with rebuilding the company's pipeline, rejecting Pfizer's 2014 takeover bid, and driving its current position as a top-tier oncology and rare disease company.
Advertisement
What is AstraZeneca's market position?
AstraZeneca is a top-10 global pharmaceutical company with $58.7 billion in 2025 revenue. It is a global leader in oncology and operates major franchises in CVRM, respiratory, and rare disease, with 16 blockbuster medicines and approximately 94,000 employees.
What are AstraZeneca's biggest products?
Tagrisso, Farxiga, Imfinzi, Lynparza, Soliris, Ultomiris, and Symbicort are among its largest products. Oncology alone generated $25.6 billion in 2025, and the company counts 16 medicines with annual sales above $1 billion.
- Founded: 1999
- Headquarters: Cambridge, England, United Kingdom
- Company Type: Publicly Traded
- Stock: London Stock Exchange (also Nasdaq): AZN
- Revenue: $58.74 billion total revenue (FY2025)
- Employees: Approximately 94,000
Where Is AstraZeneca Made / Based?
- Headquarters: Cambridge, England, United Kingdom
- Manufacturing / Operations: United Kingdom, United States, Sweden, China, Ireland
AstraZeneca Categories & Tags
AstraZeneca Sustainability & Ethics
The company runs an Ambition Zero Carbon program with validated science-based targets and publishes ESG reporting covering access-to-medicine programs and health equity initiatives. It is not B Corp certified, consistent with major pharmaceutical peers.
Brands Owned by AstraZeneca PLC
Healthcare PharmaceuticalsBydureon
Owned by AstraZeneca PLC
Exenatide extended-release weekly injectable for type 2 diabetes, owned by AstraZeneca since the 2012 Amylin Pharmaceuticals acquisition.
pharmaceuticalsprescription-drugsdiabetes
Healthcare PharmaceuticalsFarxiga
Owned by AstraZeneca PLC
Dapagliflozin SGLT2 inhibitor approved for type 2 diabetes, heart failure, and chronic kidney disease, owned by AstraZeneca since its 2014 US launch.
pharmaceuticalsprescription-drugsdiabetes
Healthcare PharmaceuticalsOnglyza
Owned by AstraZeneca PLC
Saxagliptin DPP-4 inhibitor for type 2 diabetes, acquired outright by AstraZeneca in 2014 and later discontinued in the US and Europe as generics entered the market.
diabetestype-2-diabetesdpp-4-inhibitor
Advertisement
AstraZeneca Ownership: Pros & Cons
Advantages
- +Top-ten global pharma with 14 percent oncology growth
- +16 blockbuster medicines provide diversified revenue
- +Rare disease segment adds high-margin stability
- +Industry-leading pipeline productivity
- +Dual London and Nasdaq listings provide capital access
Considerations
- -Farxiga and other key products face approaching patent cliffs
- -Medicare price negotiation exposes US revenue
- -COVID vaccine history left residual reputational issues
- -China regulatory compliance created 2024-2025 challenges
- -Large acquisitions bring integration complexity
Frequently Asked Questions About AstraZeneca
Advertisement
Sources & Further Reading
Competitors to AstraZeneca
These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.
| Brand | Parent Company | Country | Founded | Market Position | Primary Market | Gender Target |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim | Germany | 1885 | Market leader | Global | All Genders | |
| Eli Lilly | USA | 1876 | Market leader | Global | All Genders | |
| Sanofi | France | 1973 | Market leader | Global | All Genders | |
| Boehringer Ingelheim | Germany (Boehringer Ingelheim) | 2014 | Market leader | Global | All Genders | |
| Astrazeneca | United Kingdom (parent AstraZeneca) | 2012 | Niche | Global | All Genders | |
| Astrazeneca | United Kingdom (parent AstraZeneca) | 2014 | Market leader | Global | All Genders |
Learn More About Competitors
Healthcare PharmaceuticalsBoehringer Ingelheim
Owned by Boehringer Ingelheim
German family-owned pharmaceutical brand behind Jardiance and Spiriva, founded in 1885 and still controlled by the Boehringer family.
pharmaceuticalsprescription-drugsanimal-health
Healthcare PharmaceuticalsEli Lilly
Owned by Eli Lilly and Company
American pharmaceutical brand behind Mounjaro and Zepbound, owned by publicly traded Eli Lilly and Company founded in Indianapolis in 1876.
pharmaceuticalsprescription-drugsdiabetes
Healthcare PharmaceuticalsSanofi
Owned by Sanofi
French pharmaceutical brand behind Lantus and Dupixent, owned by publicly traded Sanofi SA founded in Paris in 1973.
pharmaceuticalsprescription-drugsvaccines
Healthcare PharmaceuticalsJardiance
Owned by Boehringer Ingelheim
Empagliflozin SGLT2 inhibitor for type 2 diabetes, heart failure, and kidney disease, co-marketed by Boehringer Ingelheim and Eli Lilly since its 2014 launch.
pharmaceuticalsprescription-drugsdiabetes
Healthcare PharmaceuticalsBydureon
Owned by AstraZeneca PLC
Exenatide extended-release weekly injectable for type 2 diabetes, owned by AstraZeneca since the 2012 Amylin Pharmaceuticals acquisition.
pharmaceuticalsprescription-drugsdiabetes
Healthcare PharmaceuticalsFarxiga
Owned by AstraZeneca PLC
Dapagliflozin SGLT2 inhibitor approved for type 2 diabetes, heart failure, and chronic kidney disease, owned by AstraZeneca since its 2014 US launch.
pharmaceuticalsprescription-drugsdiabetes
Competitive Analysis
Market Positioning: AstraZeneca competes with 6 brands in the same categories, ranging from mass market to luxury positioning.
Geographic Distribution: Competitors are headquartered across multiple regions, indicating global competition in this market segment.
Brand Heritage: Competitor brands range from established heritage brands to newer market entrants, with founding years spanning several decades.
Advertisement
Independent Alternatives to AstraZeneca
Looking for brands with different ownership structures? These similar brands are not owned by AstraZeneca PLC, giving you alternative choices that support different corporate structures.
Healthcare PharmaceuticalsBoehringer Ingelheim
Owned by Boehringer Ingelheim
German family-owned pharmaceutical brand behind Jardiance and Spiriva, founded in 1885 and still controlled by the Boehringer family.
pharmaceuticalsprescription-drugsanimal-health
Privately Owned
Boehringer Ingelheim is privately owned, unlike AstraZeneca which is under a publicly traded parent company.
Healthcare PharmaceuticalsJardiance
Owned by Boehringer Ingelheim
Empagliflozin SGLT2 inhibitor for type 2 diabetes, heart failure, and kidney disease, co-marketed by Boehringer Ingelheim and Eli Lilly since its 2014 launch.
pharmaceuticalsprescription-drugsdiabetes
Privately Owned
Jardiance is privately owned, unlike AstraZeneca which is under a publicly traded parent company.
Healthcare PharmaceuticalsEli Lilly
Owned by Eli Lilly and Company
American pharmaceutical brand behind Mounjaro and Zepbound, owned by publicly traded Eli Lilly and Company founded in Indianapolis in 1876.
pharmaceuticalsprescription-drugsdiabetes
Publicly Traded
Eli Lilly operates independently without a large parent corporation.
Healthcare PharmaceuticalsSanofi
Owned by Sanofi
French pharmaceutical brand behind Lantus and Dupixent, owned by publicly traded Sanofi SA founded in Paris in 1973.
pharmaceuticalsprescription-drugsvaccines
Publicly Traded
Sanofi operates independently without a large parent corporation.
Healthcare PharmaceuticalsNovo Nordisk
Owned by Novo Nordisk
Danish pharmaceutical company specializing in diabetes care and obesity treatment. Founded in 1923, headquartered in Bagsvaerd, Denmark. World leader in diabetes care and a leader in obesity treatment with Ozempic, Wegovy, and the investigational CagriSema. CEO Lars Fruergaard Jorgensen departed in March 2025; interim leadership under board chairman Helge Lund until a permanent CEO is appointed.
pharmaceuticalsdiabetesobesity
Publicly Traded
Novo Nordisk operates independently without a large parent corporation.
Healthcare PharmaceuticalsAmgen
Owned by Amgen Inc.
Master biotechnology brand of Amgen Inc., the world's largest independent biotech, covering its full portfolio of biologic medicines.
biotechnologypharmaceuticalsbiologics
Publicly Traded
Amgen operates independently without a large parent corporation.
AstraZeneca PLC Stock Information
Advertisement
Jobs at AstraZeneca PLC
Latest News About AstraZeneca
Advertisement
Related Articles About AstraZeneca
View more articles
Health
The Pharmaceutical Giants Behind Common Medicines
Eli Lilly is now #1 pharma ($65.2B, Mounjaro + Zepbound). Novo Nordisk has 59.6% GLP-1 share. Merck's Keytruda is $31.7B. Pfizer faces a $20B patent cliff. Discover who makes your medicines. Explore our database.
Who Brands StaffNov 6, 2026
PharmaceuticalsEli LillyNovo Nordisk
Health
Generic vs Brand Name Drugs: Same Company or Different
Teva is the world's largest generic drugmaker (~6% US share). Sandoz was spun off Novartis in 2023. Viatris came from Mylan + Pfizer's Upjohn. Pfizer itself holds hundreds of ANDAs. Explore our database.
Who Brands StaffOct 30, 2026
Generic DrugsBrand NamePharmaceuticals
Health
Dental Brand Ownership Beyond Colgate and Crest
Colgate holds 41.3% global toothpaste share. P&G (Crest, Oral-B) has 14.1%. Haleon (Sensodyne) has 4.4%. Church & Dwight is the only independent at scale. The oral care market is $47.2B. Explore our database.
Who Brands StaffNov 12, 2026
ColgateCrestOral B
People Also Searched
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.
Brandpharmaceutical
Abbokinase
Abbokinase (urokinase) is a thrombolytic medication historically used for pulmonary embolism and catheter clearance. Originally marketed by Abbott Laboratories, now owned by Microbix Biosystems as Kinlytic. FDA-approved since 1978.
Brand in Healthcare & Pharmaceuticals
thrombolyticurokinase
Brandmedical-devices
Abbott Medical Devices
Abbott Laboratories' medical device business spanning cardiovascular, diabetes care (FreeStyle Libre), neuromodulation, and structural heart, generating roughly $20 billion annually.
Brand in Healthcare & Pharmaceuticals
cardiovasculardiabetes-care
Brandrsv-vaccine
Abrysvo
Pfizer's respiratory syncytial virus (RSV) vaccine approved for older adults, maternal immunization to protect infants, and younger at-risk adults. Launched 2023.
Brand in Healthcare & Pharmaceuticals
vaccinesmaternal-immunization